Articles Tagged With:
-
251 hospitals get 5 stars for patient satisfaction
CMS announced the new rating system as part of an effort to standardize rating systems across its website. Hospitals could preview the ratings in 2014, but the list was finalized this year.
-
‘Immediate jeopardy’ can happen to any hospital
It can happen to those top-notch facilities, say the experts. It is possible for a serious deficiency to slip through the cracks and go unnoticed until a CMS surveyor makes a fateful note in the records.
-
IRB newsletter gives visually appealing info and updates
The Emory University IRB sends out a monthly newsletter updating IRB members about educational opportunities, new tools for review, regulatory and policy updates, and other news.
-
Variety of strategies needed to educate IRB members & chairs
Human research protection rules and regulations evolve and change, and it’s difficult for even the most experienced IRB members and chairs to keep up with them.
-
The doc who kicked the hornet’s nest: Is conflict of interest overkill stalling medical advances?
Lisa Rosenbaum, MD, a cardiologist at Brigham and Women’s Hospital in Boston, caused quite a stir earlier this year when she challenged medical orthodoxy in writing a three-part series on conflict of interest issues.
-
Research noncompliance is a problem of system failure
Every IRB and research organization should view research noncompliance as systems failures that need to be dealt with professionally, consistently, and transparently, according to an IRB expert.
-
Verbal consent and decision tree assist research community
As informed consent and IRB work evolve, new tools can help ease the transformation.
-
ANPRM Update
The U.S. Department of Health and Human Services published a Notice of Proposed Rulemaking at press time in the Office of the Federal Register.
-
AllTrials launches U.S. campaign, demands clinical trial data release
Originally founded in the UK, the AllTrials Campaign have brought their crusade for clinical trial transparency to the United States.
-
Two Drugs Better Than One for Pulmonary Arterial Hypertension
Among subjects with pulmonary arterial hypertension who are treatment naïve, initial combination therapy with tadalafil and ambrisentan is associated with significantly lower risk of clinical failure than initial monotherapy with either tadalafil or ambrisentan.